EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022

Christine Watera, Juliana de Fatima Da Silva, Grace Namayanja, Juliet Nkugwa Asio, Deogratius Ssemwanga iD, Sherri Pals iD, Miriam Nabukenya, Elliot Raizes iD, Maria Nanyonjo, Bill Elur, Esther Nazziwa, Grace Sanyu und 12 weitere

Journal of Antimicrobial Chemotherapy · 01.08.2025 · 80 (8) · 2126-2134

DOI: 10.1093/jac/dkaf180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 09.06.2025. Verfasst von Christine Watera und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Virololgy, Uganda Virus Research Institute (UVRI), Entebbe, Uganda. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, HIV Infections, Oxazines, HIV-1. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Centers for Disease Control and Prevention (U.S. CDC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives Uganda adopted dolutegravir as its preferred HIV treatment regimen in the national guidelines for treatment of HIV and AIDS in 2018. We conducted a survey to estimate dolutegravir resistance 4 years post-dolutegravir introduction in routine clinical settings. This was a cross-sectional survey to estimate the prevalence of HIV drug resistance (HIVDR) to dolutegravir among children and adults with viral non-suppression (VNS; ≥1000 copies/mL) receiving dolutegravir-based antiretroviral therapy for at least 9 months.

Methods

We used remnant specimens from routine viral load monitoring stored at Central Public Health Laboratories during February–April 2022. Genotyping of the protease, reverse transcriptase and integrase regions of the HIV-1 pol gene was done using Thermo Fisher® kits and analysed using the Stanford HIVDR database. Weighted prevalences of HIVDR with 95% confidence intervals (CI) were estimated for adults (≥15 years) and children (0–14 years).

Results

We randomly selected 857 specimens including 457 from adults and 400 from children for HIVDR testing from 3578 eligible specimens collected during February–April 2022. Five hundred and eleven (59.6%) were successfully genotyped in the integrase region. Intermediate- to high-level dolutegravir HIVDR prevalence was 3.9% (CI: 0.7, 7.1) for adults and 6.6% (CI: 3.5, 9.6) for children.

Conclusion

HIVDR to dolutegravir was uncommon but present among both children and adults with VNS after 9 months or more of exposure to dolutegravir. Additional longitudinal outcomes data are needed to determine if adherence counselling for patients with VNS on dolutegravir regimens might improve outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 3-RingHIV InfectionsOxazinesHIV-1PiperazinesViral LoadDrug Resistance, ViralHIV Integrase InhibitorsAnti-HIV AgentsHumansPyridonesUgandaCross-Sectional StudiesAdultChildMaleChild, PreschoolAdolescentFemaleInfantYoung AdultMiddle AgedPrevalenceGenotypeInfant, NewbornDolutegravir

Substanzen

PyridonesHeterocyclic Compounds, 3-RingOxazinesPiperazinesHIV Integrase InhibitorsAnti-HIV AgentsDolutegravir

Autor:innen und Institutionen

  • Department of General Virololgy, Uganda Virus Research Institute (UVRI), Entebbe, Uganda.
  • Division of Global HIV & TB, U.S. Centers for Disease Control and Prevention, Atlanta, USA.
  • Division of Global HIV & TB, U.S. Centers for Disease Control and Prevention, Kampala, Uganda.
  • Sequencing Platform, Medical Research Council (MRC)/UVRI & London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit, Entebbe, Uganda.
  • Central Public Health Laboratories, Ministry of Health, Kampala, Uganda.
  • AIDS Control Program, Ministry of Health, Kampala, Uganda.

ORCID-Profile: Deogratius Ssemwanga, Sherri Pals, Elliot Raizes

Förderung

  • U.S. Centers for Disease Control and Prevention (U.S. CDC)

Zitieren

APA

Watera, C., Da Silva, J. F., Namayanja, G., Asio, J. N., Ssemwanga, D., Pals, S., Nabukenya, M., Raizes, E., Nanyonjo, M., Elur, B., Nazziwa, E., Sanyu, G., Ayitewala, A., Ssali, M., Katureebe, C., Balidawa, H., Zheng, D. P., Zeh, C., Hackett, S., …, & Kaleebu, P. (2025). HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022. Journal of Antimicrobial Chemotherapy, 80(8), 2126-2134. https://doi.org/10.1093/jac/dkaf180

Vancouver

Watera C, Da Silva JF, Namayanja G, Asio JN, Ssemwanga D, Pals S, et al. HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022. Journal of Antimicrobial Chemotherapy. 2025;80(8):2126-2134. doi:10.1093/jac/dkaf180

BibTeX
@article{Watera2025,
  author = {Watera, Christine and Da Silva, Juliana de Fatima and Namayanja, Grace and Asio, Juliet Nkugwa and Ssemwanga, Deogratius and Pals, Sherri and Nabukenya, Miriam and Raizes, Elliot and Nanyonjo, Maria and Elur, Bill and Nazziwa, Esther and Sanyu, Grace and Ayitewala, Alisen and Ssali, Mina and Katureebe, Cordelia and Balidawa, Hudson and Zheng, Du-Ping and Zeh, Clement and Hackett, Stephanie and Mwangi, Christina and Naluguza, Mary and Ntale, Jonathan and Katongole Mbidde, Edward and Kaleebu, Pontiano},
  title = {HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  volume = {80},
  number = {8},
  pages = {2126--2134},
  doi = {10.1093/jac/dkaf180}
}
Kostenlos starten →